The first drug to treat sexual dysfunction in premenopausal women - dubbed the "female Viagra" - has received approval from the US Food and Drug Administration.
Flibanserin has been approved by the FDA to treat premenopausal women with low sexual desire.
Image credit: G. Breed/Associated PressManufactured by Sprout Pharmaceuticals, flibanserin (brand name Addyi) has been given the green light by the federal drug agency for the treatment of hypoactive sexual desire disorder (HSDD) - a condition characterized by low sexual desire.
It is estimated that around 1 in 10 women develop HSDD, and up to 40% experience the condition at some point in their lives. Psychological factors, such as low self-esteem, stress or mental health problems may contribute to low sexual desire, as well as hormone changes or physical factors, such as fatigue or lifestyle habits.
While the exact mechanisms by which flibanserin works is unclear, Sprout Pharmaceuticals believe it corrects an imbalance in brain chemicals that are responsible for sexual desire.
The US Food and Drug Administration (FDA) say a 100-mg dose of the drug should be taken once daily just before bedtime. Patients should discontinue use if they experience no improvement in sexual desire within 8 weeks.
Change Ad Consent
选择“Disable on www.wenxuecity.com”
选择“don't run on pages on this domain”
